2-Methoxyestradiol
In clinical developmentAlso known as 2-Hydroxyestradiol 2-methyl ether, 2-Hydroxyestradol 2-methyl ether, 2-ME2, 2-Methoxyestradiol-17beta+1 more
2-Hydroxyestradiol 2-methyl ether, 2-Hydroxyestradol 2-methyl ether, 2-ME2, 2-Methoxyestradiol-17beta, 2ME2.
Recent clinical, regulatory, research and industry developments relating to this drug.
Understanding of ROS-Inducing Strategy in Anticancer Therapy.
A Phase I and Pharmacologic Study of 2-Methoxyestradiol in Patients With Advanced Solid Tumors
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- Oxidative medicine and cellular longevity1
- Kim HS1
- Kim SJ1
- Seo YR1
- Dongguk University Biomedi Campus1
- Institute of Environmental Medicine for Green Chemistry1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials